As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.
By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.
Lung cancer is the leading cause of cancer death worldwide. With 433 lives claimed each day in the U.S. alone, the immense unmet need for prevention and early detection is inspiring potential breakthrough innovations worldwide. From cutting-edge imaging and diagnosis technologies to surfaceome profiling-guided treatments – impactful initiatives to prevent, intercept and treat lung cancer are on the horizon.
Â
This November, in honor of Lung Cancer Awareness Month, we’re sitting down with experts at The Lung Cancer Initiative at Johnson & Johnson and MD Anderson Lung Cancer Moon Shots as well as innovators in the field to present on and create dialogue around the core challenges faced by innovators in the field, new discoveries, emerging technologies, and potential solutions. This program will provide the opportunity to network with the innovation community, learn from experts and cultivate relationships in the lung cancer space.
Â
Source: Lung Cancer Foundation of America
